Extranodal Interdigitating Dendritic Cell Sarcoma Presenting in the Pleura: A Case Report

Han, Hye‐Suk; Lee, Ok-Jun; Lim, Sung Cil; An, Jin; Lee, Ki Man; Choe, Kang Hyeon; Kim, Seung Taik

doi:10.3346/jkms.2011.26.2.304

Cited by 24 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristic kidney-shaped nuclei have also been reported before in canine HS (33,39,46) and in human HS (47) and IDCS (14). Indentations of the nucleus have been reported in the canine literature (1,7,24,26,28) as well as in human HS (41) and IDCS (48), and a combination of indentations, grooves or folds in human HS (43,49), IDCS (14) and LCH (50). This indicates that a canine subtype comparable to human LCH/LCS may also exist.…”

Section: Discussionsupporting

confidence: 48%

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers

2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 48%

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers

2018

View full text Add to dashboard Cite

show abstract

“…Typically, cervical lymph nodes are involved, but occasionally, other lymph nodes such as in the axillary region are also affected [64,181,194,222]. Involvement of surrounding areas such as the nasal cavity, parotid gland, and pleura [72,84,116,120,157], as well as the genital area and the intestinal tract has also been described [93,120,127]. Whereas the tumor masses usually are the first clinical symptom, systemic symptoms like fever or fatigue may occur in advanced stages [194].…”

Section: Interdigitating Dendritic Cell Sarcoma (Idcs) (Interdigitatimentioning

confidence: 99%

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

2016

View full text Add to dashboard Cite

Rare histiocytoses, also called non-Langerhans cell histiocytoses, include all proliferative disorders of histiocytes, macrophages and dendritic cells that are not classified as Langerhans cell histiocytosis (LCH) and do not belong to the hemophagocytic lymphohistiocytosis (HLH) group of diseases. Thus, the term includes numerous benign or malignant, localized or systemic, adult or pediatric diseases. The classification of the histiocytic disorders has been revised several times. Here, we follow the classification recently published by Jean Francois Emile and an international expert panel, defining subgroups of histiocytoses described as L-Group, C-Group, M-Group, R-Group, and H-Group, which stands for LCH-like, cutaneous or mucocutaneous, malignant, Rosai-Dorfman-Disease like and HLH like. Some of the diseases have an excellent prognosis after resection or even disappear spontanously, others progress rapidly, requiring intensive systemic therapies. The malignant non-Langerhans cell histiocytoses in general have a poor prognosis, here, complex chemotherapy protocols are usually applied, with inconsistant results. An interesting perspective in non-malignant rare histiocytoses might be small molecular inhibitors, in particular BRAF inhibitors, since BRAF mutations have been found in some subtypes of non-Langerhans cell histiocytoses. By prospective and retrospective collection of experiences in a new registry (the "International Rare Histiocytic Disorders Registry", IRHDR), knowledge about these rare diseases might hopefully be improved.

show abstract

“…1,2 The tumor usually initially develops at the Tcell-rich region of the lymph node, although the involvement of extra-nodal sites such as the spleen, intestine, testis, urinary bladder, lung, kidney, and bone marrow has also been reported. [3][4][5][6][7][8][9] Cutaneous lesions are extremely rare, and fewer than 10 cases have been reported. 10,11 Although various treatments such as surgery, radiation therapy, chemotherapy, and hematopoietic stem cell trans-plantation have been attempted, there is no consensus on the preferred treatment.…”

Section: Introductionmentioning

confidence: 99%

Complete Remission in Systemic Skin Interdigitating Dendritic Cell Sarcoma after ABVD Chemotherapy

Kyogoku

Seki

Ogawa

et al. 2015

JCEH

View full text Add to dashboard Cite

Interdigitating dendritic cell sarcoma (IDCS) is a rare and aggressive neoplasm that is thought to arise from dendritic cells. This disease usually involves the lymph nodes and, rarely, extra-nodal sites. We report a 62-year-old man presenting skin nodules in the head, body, and extremities, as well as bone marrow involvement. Morphologic analysis of a biopsied specimen from the skin lesion was consistent with IDCS. Immunohistochemical staining demonstrated that the tumor cells were positive for IDCS-associated antigens such as CD4, CD45, CD68 (KP-1), and S-100 protein. Complete remission was achieved by treatment with 6 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) chemotherapy. Although the optimal treatment of IDSC remains unknown, the experience in the current case supports the notion that ABVD chemotherapy may be effective for IDCS, and further extends this idea to rare patients presenting multiple skin lesions.

show abstract

Extranodal Interdigitating Dendritic Cell Sarcoma Presenting in the Pleura: A Case Report

Cited by 24 publications

References 13 publications

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

Complete Remission in Systemic Skin Interdigitating Dendritic Cell Sarcoma after ABVD Chemotherapy

Contact Info

Product

Resources

About